PFIZER INC: directors' dealings · United States · SEC (Form 4)

About PFIZER INC

Pfizer Inc. is a global biopharmaceutical company listed in the United States on the NYSE under the ticker PFE, with its global headquarters in New York, New York (United States). Founded in 1849 in Brooklyn by Charles Pfizer and Charles Erhart, Pfizer has evolved from a small chemical business into one of the world’s most recognized pharmaceutical groups. Its business model is centered on discovering, developing, manufacturing, and commercializing medicines and vaccines for major unmet medical needs. Pfizer’s core operations are concentrated in innovative pharmaceuticals and vaccines, supported by capabilities in biologics and biosimilars. The company spans several major therapeutic areas, including oncology, rare disease, inflammation and immunology, internal medicine, infectious disease, and vaccines. Its portfolio includes a mix of established franchises and newer assets from ongoing R&D, allowing the company to balance near-term commercial cash flows with longer-term innovation. Well-known brands and platforms include the Prevnar pneumococcal vaccine franchise, COVID-19 vaccine products developed with BioNTech, and a range of specialty medicines across oncology and cardiovascular/metabolic care. Pfizer also emphasizes its biosimilars platform and its global manufacturing strength. From a competitive standpoint, Pfizer remains a large-scale leader in global pharma due to its breadth, pipeline depth, industrial footprint, and commercial reach. The company operates 36 manufacturing sites worldwide and sells products in about 200 countries and territories, giving it one of the broadest geographic footprints in the industry. That scale is strategically important in a sector where regulatory execution, manufacturing reliability, and access to markets are critical to sustaining long-term growth. Recent developments underscore Pfizer’s focus on pipeline execution and portfolio optimization. In its May 5, 2026 quarterly update, the company reported solid first-quarter results and reaffirmed its 2026 guidance. Pfizer also highlighted recent regulatory and clinical progress, including European approval for HYMPAVZI in hemophilia with inhibitors and positive advances for ELREXFIO in relapsed or refractory multiple myeloma. These updates suggest that management is working to offset patent-expiry pressure and legacy COVID-related normalization with new launches and late-stage pipeline assets. For investors, Pfizer offers a combination of defensive qualities and growth optionality: a large diversified franchise, a strong global manufacturing base, a well-known brand in vaccines and specialty medicines, and a pipeline intended to support the post-LOE period. As a U.S.-listed company on the NYSE, Pfizer remains a key reference name in large-cap healthcare exposure.